Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq analysis of cell lines established from patient-derived luminal breast cancer xenografts

ABSTRACT: Breast cancer cell lines from PDX models

ORGANISM(S): Homo sapiens

PROVIDER: GSE146024 | GEO | 2020/06/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNAseq analysis of cell lines established from patient-derived luminal breast cancer xenografts

Project description:RNAseq analysis of cell lines established from patient-derived luminal breast cancer xenografts

| PRJNA609071 | ENA

RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93057 | GEO

Deep Protein Arginine Asymmetric Di-Methylation Profiling of Breast Cancer Patient-derived Xenografts

Project description:Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is a prevalent posttranslational modification that regulates diverse cellular processes. Aberrant expression of type I PRMTs that catalyze asymmetric arginine demethylation (ADMA) is often found in cancer; however, little is known about the ADMA status of substrate proteins in tumors. Using LC-MS/MS along with pan-specific ADMA antibodies, we performed global mapping of ADMA in five patient-derived xenograft (PDX) tumors representing different subtypes of human breast cancer and identified 415 methylated peptides from 213 proteins. Approximately 70% of the putative substrates were validated using peptide arrays in vitro methylated by PRMT1, PRMT4, and PRMT6, among which 48% of substrates varied from estrogen receptor (ER) positive and negative tumors. Comparing with our previously identified ADMA sites from breast cancer cell lines, 75 ADMA sites overlapped between cell lines and PDX tumors. Collectively, this study provides a useful resource to PRMT and breast cancer communities to exploit the functions of PRMT dysregulation during breast cancer progression.

2024-01-26 | PXD038203 | Pride

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2022-08-12 | GSE136260 | GEO

Estrogen and progesterone receptor dynamics in patient-derived luminal breast cancer xenografts

Project description:Progesterone receptors (PR) are co-expressed in over half of estrogen receptor (ER) positive breast cancers and predict positive response to endocrine therapy. PR can directly and globally modify ER action to attenuate tumor growth. However, whether this suppression occurs solely through PR-ER interactions remains unknown. We assessed tumor growth in two highly ER and PR positive breast cancer patient-derived xenografts (PDX) and found that natural and synthetic progestins potently antagonize the mitogenic effects of estrogens. Here we probed the genome-wide mechanisms by which this occurs. Chronic progestin treatment reversed expression of up to half of estrogen up- and downregulated genes at the transcript level. However, fewer than a quarter of ER DNA binding events were altered by progesterone. The PR cistrome showed an interesting bimodal distribution. In the first group, more than half of PR binding sites were co-occupied by ER, with a propensity for both receptors to coordinately gain or lose binding in the presence of progesterone. In the second group, PR, but not ER, was associated with a large fraction of RNA polymerase III (Pol III)-transcribed tRNA genes regardless of hormone treatment. Furthermore, PR formed a physical association with the Pol III holoenzyme. Select tRNAs with colocalization of PR and POLR3A at their promoters were reduced in tumors grown with estrogen plus progestin compared to estrogen alone. These data uncover a mechanism in solid tumors by which PR modulates the bioavailability of translational molecules that are necessary for robust tumor growth, which could indirectly impede ER action.

2017-02-28 | GSE93944 | GEO

ChIPseq analysis of patient-derived luminal breast cancer xenografts with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93108 | GEO

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2013-02-24 | GSE36075 | GEO

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts Two primary xenografts with different treatments

2013-02-24 | E-GEOD-36075 | biostudies-arrayexpress

Patient-derived luminal breast cancer xenografts with progestins

Project description:Patient-derived luminal breast cancer xenografts with progestins